Amoy Diagnostics AmoyDx Pan Lung Cancer PCR Panel
Amoy Diagnostics and Premia have launched the AmoyDx Pan Lung Cancer PCR Panel in Japan as a reimbursed companion diagnostic for multiple anti-cancer agents. The panel was conceived by AmoyDx, who also manufactures it, and developed in Japan by Premia. It uses real-time PCR to evaluate 11 driver genes. In Japan, the use of five driver genes on the panel has been approved as a companion diagnostic for 10 targeted therapies for non-small cell lung cancer.
Akoya Biosciences PhenoCycler-Fusion System
Akoya Biosciences has launched the PhenoCycler-Fusion system for high-speed imaging of slides at single-cell and sub-cellular resolution. The platform combines the strengths of the firm's automated, high-multiplex cycling platform PhenoCycler (previously branded as Codex) and its high-speed imaging platform PhenoImager (previously branded as Phenoptics) into an integrated workflow. In addition to protein biomarkers, the system can detect RNA, using RNAScope assays developed in collaboration with Bio-Techne. It can detect more than 100 markers for deep spatial phenotyping and map every cell across a tissue section, including from FFPE slides. It is capable of processing more than 100 slides per week, according to the company.
Congenica 'Sample to Report' Service
Congenica has expanded its clinical consulting services by introducing a "sample to report" service. The UK-based company said that the new offering will support clinical laboratories with constrained capacity by connecting them with sequencing partners to conduct panel, whole-exome, and whole-genome sequencing. Congenica can then perform data analysis and clinical interpretation, and, where allowed by law, sign off on reports on behalf of its clients.
Lucence LiquidHallmark Expanded Assay
Lucence has launched an expanded version of its flagship LiquidHallmark liquid biopsy assay that includes both cell-free DNA and RNA profiling. The combined panel, available for US customers as a laboratory-developed test, includes cfRNA profiling of 27 actionable and emerging gene fusions and cfDNA profiling of mutations in 80 genes and fusions in 10 genes. The assay is powered by AmpliMark, the company’s proprietary amplicon-based sequencing technology, which uses molecular barcode and error-correction technology.
For more new products and services, please visit the New Products page on our website.